Roche kicks off 2019 with group sales up 8%; raises outlook

17 April 2019

Swiss pharma giant Roche (ROG: SIX) this morning reported that, in the first three months of 2019, Group sales rose 8% to 14.8 billion Swiss francs ($14.75 billion), beating the 14.2 billion forecast in a Reuters poll.

Sales in the Pharmaceuticals Division increased 10% to 11.9 billion francs, beating the 11.2 billion francs poll average, while diagnostics sales edged higher. Roche, the world's biggest cancer drug maker, does not release profit figures at the first quarter stage, and will disclose earnings after the first half of the year.

Sales growth in China and the USA outpaced price declines the company has suffered amid President Donald Trump's pressure on the industry to hold down charges.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK